Impaired type I and type III interferon induction and rhinovirus control in human cystic fibrosis airway epithelial cells

Thorax. 2012 Jun;67(6):517-25. doi: 10.1136/thoraxjnl-2011-200405. Epub 2012 Jan 2.

Abstract

Background: Rhinoviruses are important triggers of pulmonary exacerbations and possible contributors to long-term respiratory morbidity in cystic fibrosis (CF), but mechanisms leading to rhinovirus-induced CF exacerbations are poorly understood. It is hypothesised that there is a deficient innate immune response of the airway epithelium towards rhinovirus infection in CF.

Methods: Early innate immune responses towards rhinoviruses (RV-16, major-type and RV-1B, minor-type) in CF and non-CF bronchial epithelial cell lines and primary nasal and bronchial epithelial cells from patients with CF (n=13) and healthy controls (n=24) were studied.

Results: Rhinovirus RNA expression and virus release into supernatants was increased more than tenfold in CF cells compared with controls. CF cells expressed up to 1000 times less interferon (IFN) type I (β) and type III (λ) mRNA and produced less than half of IFN-β and IFN-λ protein compared with controls. In contrast, interleukin 8 production was not impaired, indicating a selective deficiency in the innate antiviral defence system. Deficient IFN production was paralleled by lower expression of IFN-stimulated genes including myxovirus resistance A, 2',5'-oligoadenylate synthetase, viperin and nitric oxide synthase 2. Addition of exogenous type I and III IFNs, particularly IFN-β, restored antiviral pathways and virus control in CF cells, underscoring the crucial role of these molecules.

Conclusions: This study describes a novel mechanism to explain the increased susceptibility of patients with CF to rhinovirus infections. A profound impairment of the antiviral early innate response in CF airway epithelial cells was identified, suggesting a potential use of IFNs in the treatment of rhinovirus-induced CF exacerbations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Acute Disease
  • Antiviral Agents / immunology
  • Antiviral Agents / pharmacology*
  • Bronchi / cytology
  • Bronchi / immunology*
  • Bronchi / virology
  • Cells, Cultured
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / immunology*
  • Cystic Fibrosis / virology
  • Disease Susceptibility
  • Epithelial Cells / immunology
  • Epithelial Cells / virology
  • Humans
  • Immunity, Innate / drug effects
  • Interferon Type I / immunology
  • Interferon-beta / deficiency
  • Interferon-beta / immunology*
  • Interferon-beta / pharmacology
  • Interferons / deficiency*
  • Interferons / immunology
  • Interleukins / deficiency
  • Interleukins / immunology*
  • Picornaviridae Infections / drug therapy
  • Picornaviridae Infections / immunology*
  • Picornaviridae Infections / metabolism
  • Picornaviridae Infections / virology
  • Podocytes / immunology
  • Respiratory Mucosa / immunology*
  • Respiratory Mucosa / virology*
  • Rhinovirus / drug effects
  • Rhinovirus / immunology*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • interferon-lambda, human
  • Interferon Type I
  • Interleukins
  • Interferon-beta
  • Interferons